Frank J Riske, Ph.D., Senior Consultant of BioProcess Technology Consultants, has over 25 years of experience in the biopharmaceutical industry and has been involved in the development, or improvement, of eight commercial protein products.
Prior to joining BioProcess Technology Consultants, Dr. Riske was a Senior Director in the Late Phase Process Development Group at Genzyme, a Sanofi company. At Genzyme, Dr. Riske was responsible for the development of late stage downstream processes for recombinant enzymes, monoclonal antibodies and Adenovirus (gene therapy) and the identification and exploration of new technologies, including continuous processing, to streamline and improve purification.
Prior to joining Genzyme, Dr. Riske managed the development, implementation and manufacture of a peptide bound within a novel sustained release vehicle at Epic Therapeutics. Before Epic, Dr. Riske held positions at Repligen and Hoffmann-LaRoche during which he developed and improved, downstream processes for proteins produced in mammalian cell culture, E. coli, and Pichia systems. Dr. Riske was also responsible for the manufacture of MAb fragments at Repligen.
Dr. Riske has published over 20 peer reviewed papers and patents and is active in the scientific community as both a mentor to young scientists and as a conference speaker and organizer. He is also on the Advisory Board for the Biotechnology Journal.
Dr. Riske received his B.S. in Biology from Fairfield University, Ph.D. in Biochemistry and Microbiology from Rutgers University and completed a postdoctoral position at Hoffmann-LaRoche.